BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $545,218 | -35.0% | 14,447 | -21.5% | 0.06% | -38.0% |
| Q2 2023 | $838,649 | +17.4% | 18,408 | +4.5% | 0.09% | +21.1% |
| Q1 2023 | $714,229 | -20.9% | 17,609 | -0.6% | 0.08% | -26.2% |
| Q4 2022 | $903,297 | -3.9% | 17,722 | +1.5% | 0.10% | -5.5% |
| Q3 2022 | $940,000 | -24.8% | 17,459 | -10.3% | 0.11% | -16.2% |
| Q2 2022 | $1,250,000 | -15.8% | 19,468 | +1.7% | 0.13% | -3.0% |
| Q1 2022 | $1,485,000 | -19.7% | 19,151 | -11.1% | 0.13% | -3.6% |
| Q4 2021 | $1,849,000 | +11.5% | 21,542 | +4.5% | 0.14% | +2.2% |
| Q3 2021 | $1,658,000 | +21.4% | 20,609 | +21.5% | 0.14% | +19.3% |
| Q2 2021 | $1,366,000 | -5.1% | 16,966 | -0.6% | 0.11% | -13.0% |
| Q1 2021 | $1,440,000 | +5.2% | 17,070 | +0.1% | 0.13% | -3.0% |
| Q4 2020 | $1,369,000 | -0.5% | 17,059 | -0.3% | 0.14% | -11.8% |
| Q3 2020 | $1,376,000 | -17.9% | 17,116 | -12.1% | 0.15% | -23.1% |
| Q2 2020 | $1,676,000 | +26.0% | 19,466 | +18.8% | 0.20% | +7.0% |
| Q1 2020 | $1,330,000 | -52.0% | 16,381 | -50.5% | 0.19% | +27.4% |
| Q4 2019 | $2,772,000 | +104.4% | 33,110 | +113.6% | 0.15% | -21.1% |
| Q3 2019 | $1,356,000 | – | 15,499 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |